连接组织疾病与肺动脉高血压相关的分子病变:叙述性综述
Fu-Chiang Yeh1, I-Ting Tsai2, I-Tsu Chyuan3,4,5
1Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114202, Taiwan.
连接组织疾病相关的肺动脉高血压 (CTD-PAH) 涉及肺动脉中复杂的分子变化. 本综述详细介绍了CTD-PAH病原体,生物标志物和免疫失调,以获得更好的治疗策略.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 肺部医学 肺部医学
背景情况:
- 肺动脉高血压 (PAH) 是一种严重的疾病,其特点是肺动脉重塑,导致右心力衰竭.
- 与结合性组织疾病 (CTD-PAH) 相关的PAH存在独特的挑战,通常对标准疗法反应较低.
- 系统性硬化是与PAH相关的最常见的CTD,而其他如系统性红斑狼的理解较少.
研究的目的:
- 审查PAH的一般病理生物学.
- 要突出最近在CTD-PAH的分子病原发生的进展.
- 在CTD-PAH中探索潜在的血清生物标志物和免疫失调.
主要方法:
- 综合性文献综述,重点关注CTD-PAH的分子病变发生.
- 对内皮功能障碍,细胞增殖,血管改造和血栓形成的研究进行分析.
- 在CTD-PAH中研究遗传因素,免疫反应,自身抗体,细胞因子和化学因子.
- 对CTD-PAH研究的相关动物模型的审查.
主要成果:
- CTD-PAH的发病包括内皮功能障碍,异常细胞增殖,血管重塑和细胞外基质变化.
- 免疫失调,包括特定的自身抗体,细胞因子和化学因子,在CTD-PAH中起着重要作用.
- 遗传因素和局部血栓形成有助于疾病的进展.
- 右心室功能障碍是高级CTD-PAH的关键后果.
结论:
- 了解CTD-PAH复杂的分子机制对于开发向疗法至关重要.
- 生物标志物和免疫特征为改善诊断和治疗监测提供了潜力.
- 动物模型是阐明CTD-PAH病原体和测试新型治疗干预措施的重要工具.
更多相关视频
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Peripheral Artery Disease I: Introduction
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Rheumatic Heart Disease I: Introduction
